Inhibrx Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INBX research report →
Range $245 – $325
Price Chart
About the company
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function.
- CEO
- Mark Lappe
- IPO
- 2024
- Employees
- 110
- HQ
- La Jolla, CA, US
Get TickerSpark's AI analysis on INBX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.39B
- P/E
- -10.69
- Fwd P/E
- 35.56
- PEG
- -0.57
- P/S
- 0.00
- P/B
- -28.08
- EV/EBITDA
- -10.50
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1893.60%
- ROIC
- -99.35%
Latest fiscal year · YoY change
- Revenue
- $1.30M+550.0%
- Gross Profit
- $-1,183,000+43.3%
- Op Income
- $-135,025,000
- Net Income
- $-140,055,000-108.3%
- EPS
- $-9.04-107.8%
- OCF Growth
- +33.2%
- FCF Growth
- +34.1%
- 52W High
- $155.29
- 52W Low
- $28.16
- 50D MA
- $102.24
- 200D MA
- $91.14
- Beta
- 3.67
- RSI (14)
- 38
- Avg Volume
- 300.78K
No earnings-call transcripts are available for INBX yet.
- Free Float
- 74.1%
- Shares Outstanding
- 14.67M
- Float Shares
- 10.87M
of shares held by institutions
147 13F filers
Buy/sell ratio 2.80. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 1.31M | ▲ 44.97K |
| Perceptive Advisors LLC | 1.30M | ▼ 144.94K |
| Sanofi | 1.16M | 0 |
| Viking Global Investors LP | 1.12M | ▼ 313.78K |
| Hightower Advisors, LLC | 870.55K | ▲ 351 |
| Bank Of America Corp | 841.14K | ▲ 808.46K |
| Blackrock, Inc. | 825.97K | ▲ 27.07K |
| Schonfeld Strategic Advisors LLC | 697.59K | ▲ 442.76K |
| State Street Corp | 640.46K | ▲ 89.61K |
| Vanguard Group Inc | 623.08K | ▲ 28.17K |
| Vanguard Capital Management LLC | 492.48K | ▲ 6.05K |
| Woodline Partners LP | 400.89K | ▲ 16.46K |
Held by 199 ETFs
Biggest fund positions in INBX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 28, 26 | Lappe Mark | buy | 3,000 |
| Sep 28, 26 | Lappe Mark | buy | 1,500 |
| Sep 25, 26 | Lappe Mark | buy | 2,176 |
| Sep 25, 26 | Lappe Mark | buy | 3,324 |
| Sep 23, 26 | Kayyem Jon Faiz | buy | 5,000 |
| Jun 3, 26 | FORSYTH DOUGLAS | other | 10,000 |
| Jun 3, 26 | Vuori Kristiina MD | other | 10,000 |
| Jun 3, 26 | MANHARD KIMBERLY | other | 10,000 |
| Jun 3, 26 | Kayyem Jon Faiz | other | 10,000 |
| Sep 16, 26 | Kayyem Jon Faiz | buy | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INBX coverage
Recent articles, reports, and earnings notes.
No research on INBX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INBX report →Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
defenseworld.net · Oct 5
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
marketbeat.com · Oct 2
Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying Activity
defenseworld.net · Sep 30
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 3.7% Following Insider Buying Activity
defenseworld.net · Sep 30
Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Jon Faiz Kayyem Buys 5,000 Shares
defenseworld.net · Sep 25
Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) Director Purchases $500,000.00 in Stock
defenseworld.net · Sep 20
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
fool.com · Sep 15
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106
seekingalpha.com · Sep 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.